Street Calls of the Week
Dawn Christine Maroney, President of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold a total of 215,662 shares of common stock on September 10, 2025, generating approximately $3,539,432. The sale comes as the healthcare company, currently valued at $3.27 billion, has delivered an impressive 53% return over the past year. According to InvestingPro analysis, the stock’s RSI indicates overbought territory.
The sales were executed in three separate transactions. The first two transactions involved the sale of 108,439 shares at weighted average prices of $16.2293 and $16.8555, respectively, for a total value of $1,779,228. Prices for these shares ranged from $15.74 to $17.24. The final transaction involved the sale of 107,223 shares at a price of $16.4163, totaling $1,760,204. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2025. While currently unprofitable, InvestingPro data indicates analysts expect ALHC to turn profitable this year, with the next earnings report due October 30, 2025.
Following these transactions, Maroney directly owns 1,797,237 shares of Alignment Healthcare, Inc. Get deeper insights into ALHC’s valuation and 8 additional key ProTips with InvestingPro, including comprehensive analysis of the company’s financial health and growth prospects.
In other recent news, Alignment Healthcare reported its second-quarter 2025 earnings, with earnings per share (EPS) of $0.07, significantly surpassing the projected -$0.07. The company’s revenue reached $1 billion, exceeding the forecast of $960.51 million, highlighting strong business growth. In response to these solid earnings, Barclays upgraded Alignment Healthcare’s stock from Underweight to Equalweight, raising its price target from $9.00 to $13.00. Additionally, KeyBanc upgraded the stock from Sector Weight to Overweight, setting a price target of $21.00, citing the company’s improved hospital utilization and reinvestment into member benefits. Furthermore, Alignment Healthcare announced the appointment of Matt Eyles as executive vice president of government and business strategy. His role will involve enhancing the company’s engagement in healthcare policy at federal and state levels. These developments reflect ongoing strategic initiatives and positive financial performance for Alignment Healthcare.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.